These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24957322)

  • 1. Minimal supportive treatment in natalizumab-related PML in a MS patient.
    Lalive PH; Bridel C; Ferfoglia RI; Kaiser L; Du Pasquier R; Barkhof F; Haller S
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):354-5. PubMed ID: 24957322
    [No Abstract]   [Full Text] [Related]  

  • 2. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
    Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
    [No Abstract]   [Full Text] [Related]  

  • 3. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
    Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
    Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI].
    Gibelin N; Daelman L; Goulipian S; Wynckel A; Chaunu MP; Tourbah A
    Rev Neurol (Paris); 2014 Jan; 170(1):48-50. PubMed ID: 24139244
    [No Abstract]   [Full Text] [Related]  

  • 7. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Marousi S; Travasarou M; Karageorgiou CE; Gheuens S; Koralnik IJ
    Neurology; 2012 Nov; 79(21):2160; author reply 2160. PubMed ID: 23170016
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
    Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.
    Phan-Ba R; Lommers E; Tshibanda L; Calay P; Dubois B; Moonen G; Clifford D; Belachew S
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):224-6. PubMed ID: 22013244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Ercan MB; Kocer B; Altiparmak T; Arslan I
    Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
    [No Abstract]   [Full Text] [Related]  

  • 11. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
    Hoepner R; Ahlbrecht J; Faissner S; Schneider R; Dahlhaus S; Adams O; Raab P; Lukas C; Chan A; Stangel M; Gold R
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1177-8. PubMed ID: 24700881
    [No Abstract]   [Full Text] [Related]  

  • 13. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.
    Igra MS; Paling D; Wattjes MP; Connolly DJA; Hoggard N
    Br J Radiol; 2017 Jun; 90(1074):20160721. PubMed ID: 28362522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
    Tortorella C; Direnzo V; D'Onghia M; Trojano M
    Neurology; 2013 Oct; 81(16):1470-1. PubMed ID: 24127190
    [No Abstract]   [Full Text] [Related]  

  • 17. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Hodel J; Bapst B; Outteryck O; Verclytte S; Deramecourt V; Benadjaoud MA; Pruvo JP; Vermersch P; Leclerc X
    Mult Scler; 2018 Dec; 24(14):1902-1908. PubMed ID: 29343163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C; Mausberg AK; Stettner M; Dehmel T; Nekrich L; Meyer zu Horste G; Hartung HP; Fogdell-Hahn A; Adams O; Kieseier BC
    Neurology; 2013 Oct; 81(16):1400-8. PubMed ID: 24049136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
    Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
    J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G; Renard D; Thouvenot E; Servillo G; Castelnovo G
    J Neurol Sci; 2014 Nov; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.